As of May 23, 2025, Verve Therapeutics Inc (VERV) reports a Current Ratio of 12.65.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Verve Therapeutics Inc's Current Ratio
Over recent years, Verve Therapeutics Inc's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2024-12-31 | 12.65 |
| 2023-12-31 | 17.24 |
| 2022-12-31 | 16.05 |
| 2021-12-31 | 16.69 |
| 2020-12-31 | 10.14 |
This slight upward trend highlights how Verve Therapeutics Inc manages its short-term assets and liabilities over time.
Comparing Verve Therapeutics Inc's Current Ratio to Peers
To better understand Verve Therapeutics Inc's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Verve Therapeutics Inc (VERV) | 12.65 |
| Neoimmunetech Inc (950220.KQ) | 5.61 |
| Regeneron Pharmaceuticals Inc (REGN) | 4.73 |
| Moderna Inc (MRNA) | 3.67 |
| Vertex Pharmaceuticals Inc (VRTX) | 2.69 |
| Psomagen Inc (950200.KQ) | 2.56 |
Compared to its competitors, Verve Therapeutics Inc's Current Ratio is higher than all peers, indicating strong short-term financial flexibility but potentially excess cash that could be invested.